ethyl N-(2-chloroethyl)carbamate

We are ethyl N-(2-chloroethyl)carbamate CAS:6329-26-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:ethyl N-(2-chloroethyl)carbamate
CAS.NO:6329-26-6
Synonyms:ethyl N-(2-chloroethyl)carbamate
(2-Chlor-aethyl)-urethan
(2-chloro-ethyl)-carbamic acid ethyl ester
Ethyl 2-chloroethylcarbamate
2-chloroethyl ethylcarbamate
(2-Chlor-aethyl)-carbamidsaeure-aethylester
 
Physical and Chemical Properties:
Density 1.124 g/cm3
Boiling Point 225.9ºC at 760 mmHg
Molecular Formula C5H10ClNO2
Molecular Weight 151.59100
Index of Refraction 1.438
 
Specification:
Appearance:Light yellow to brown liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Fenoxycarb(CAS:79127-80-3).

ethyl N-(2-chloroethyl)carbamate


Related News: Pharmaceutical intermediates and APIs belong to the fine chemical industry.3,5-dimetil-4-nitro-1-oxidopiridin-1-ium CAS:14248-66-9 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?1H, 1H, 2H, 2H-Perfluorooctiltrietoxisilano CAS:51851-37-7 The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.N-(3-(5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.

Related Products
Product Name
o-Tolunitrile View Details
2-bromo-6-(trifluoromethyl)aniline View Details
6-bromohex-1-ene View Details
4-Chlorobenzo[d]thiazol-2(3H)-one manufacturer phenyl isothiocyanate manufacturer 1-bromo-2-iodoethane manufacturer [1-Methyl-5-bis(2′-hydroxyethyl)aminobenzimidazolyl-2]butanoic acid ethyl ester manufacturer 1-Bromo-2-nitrobenzene manufacturer